Literature DB >> 8268970

Lymphocyte subsets in a large cohort of patients with systemic lupus erythematosus.

F Erkeller-Yüsel1, F Hulstaart, I Hannet, D Isenberg, P Lydyard.   

Abstract

In search of markers of disease activity in patients with SLE we have investigated blood lymphocyte subsets from a large cohort of patient. Seventy-one patients were studied using a well-defined panel of fluorescent monoclonal antibodies which recognize the major T, B and NK lymphocyte subsets and activated cells. Flow cytometry was used with standard automated software. Overall, SLE patients were lymphopenic. The proportion of activated T cells was increased and NK cells were decreased in both proportion and absolute numbers (P < 0.001). This decrease was more pronounced in the more active patients. None of the T cell activation markers was shown to distinguish different degrees of disease activity. However, the percentage of NK cells was significantly reduced in active disease states (P < 0.01). Decreased numbers of NK cells could potentially reduce the resistance of SLE patients to infectious organisms.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8268970     DOI: 10.1177/096120339300200404

Source DB:  PubMed          Journal:  Lupus        ISSN: 0961-2033            Impact factor:   2.911


  23 in total

Review 1.  Natural killer cells and their receptors in multiple sclerosis.

Authors:  Gurman Kaur; John Trowsdale; Lars Fugger
Journal:  Brain       Date:  2012-06-25       Impact factor: 13.501

2.  Effect of mycophenolate mofetil on the white blood cell count and the frequency of infection in systemic lupus erythematosus.

Authors:  Ananta Subedi; Laurence S Magder; Michelle Petri
Journal:  Rheumatol Int       Date:  2015-04-03       Impact factor: 2.631

Review 3.  Natural killer cells in human autoimmune diseases.

Authors:  Nicolas Schleinitz; Frédéric Vély; Jean-Robert Harlé; Eric Vivier
Journal:  Immunology       Date:  2010-10-13       Impact factor: 7.397

Review 4.  Could Lymphocyte Profiling be Useful to Diagnose Systemic Autoimmune Diseases?

Authors:  Guillermo Carvajal Alegria; Pierre Gazeau; Sophie Hillion; Claire I Daïen; Divi Y K Cornec
Journal:  Clin Rev Allergy Immunol       Date:  2017-10       Impact factor: 8.667

5.  Changes in immune cell frequencies after cyclophosphamide or mycophenolate mofetil treatments in patients with systemic lupus erythematosus.

Authors:  Ling Zhao; Zhenyu Jiang; Yanfang Jiang; Ning Ma; Kai Wang; Yandong Zhang
Journal:  Clin Rheumatol       Date:  2012-02-21       Impact factor: 2.980

6.  Natural killer cell activity in families of patients with systemic lupus erythematosus: demonstration of a killing defect in patients.

Authors:  M R J Green; A S M Kennell; M J Larche; M H Seifert; D A Isenberg; M R Salaman
Journal:  Clin Exp Immunol       Date:  2005-07       Impact factor: 4.330

7.  Assay of T- and NK-cell subsets and the expression of NKG2A and NKG2D in patients with new-onset systemic lupus erythematosus.

Authors:  Wen-Xian Li; Hai-Feng Pan; Jian-Li Hu; Chang-Zhong Wang; Ning Zhang; Jing Li; Xiang-Pei Li; Jian-Hua Xu; Dong-Qing Ye
Journal:  Clin Rheumatol       Date:  2009-12-10       Impact factor: 2.980

8.  Increased proportion of CD56bright natural killer cells in active and inactive systemic lupus erythematosus.

Authors:  Danika Schepis; Iva Gunnarsson; Maija-Leena Eloranta; Jon Lampa; Stefan H Jacobson; Klas Kärre; Louise Berg
Journal:  Immunology       Date:  2008-06-18       Impact factor: 7.397

9.  Identification of new SLE-associated genes with a two-step Bayesian study design.

Authors:  D L Armstrong; A Reiff; B L Myones; F P Quismorio; M Klein-Gitelman; D McCurdy; L Wagner-Weiner; E Silverman; J O Ojwang; K M Kaufman; J A Kelly; J T Merrill; J B Harley; S-C Bae; T J Vyse; G S Gilkeson; P M Gaffney; K L Moser; C Putterman; J C Edberg; E E Brown; J Ziegler; C D Langefeld; R Zidovetzki; C O Jacob
Journal:  Genes Immun       Date:  2009-05-14       Impact factor: 2.676

10.  Pattern of DAP12 expression in leukocytes from both healthy and systemic lupus erythematosus patients.

Authors:  Nicolas Schleinitz; Laurent Chiche; Sophie Guia; Gaëlle Bouvier; Julie Vernier; Alexis Morice; Elisabeth Houssaint; Jean Robert Harlé; Gilles Kaplanski; Félix A Montero-Julian; Frédéric Vély
Journal:  PLoS One       Date:  2009-07-16       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.